• Explore /
  • Poster
  • / A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.

A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.

Abstract Poster

Authors

null

Chunmei Bai

Department of medical onclogy, Peking Union Medical College Hospital, Beijing, China

Chunmei Bai , Junli Xue , Yi Zheng , Meili Sun , Jieer Ying , Fuxiang Zhou , Yiyi Yu , Yuping Sun , Ligang Xing , Yanqiao Zhang , Jinhua Wen , Jianping Xiong , Heshui Wu , Xiuli Yang , Lixin Wan , Shiwei Guo , Rusen Zhao , Zhizhen Zhu , Zhihua Gong , Jin Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT05161390

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 3028)

DOI

10.1200/JCO.2024.42.16_suppl.3028

Abstract #

3028

Poster Bd #

173

Abstract Disclosures

Similar Posters

First Author: Dan Liu

First Author: Brian Gastman

Poster

2020 Gastrointestinal Cancers Symposium

Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

First Author: Jifang Gong

First Author: Kanwal Pratap Singh Raghav